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Abstract  
Genome-wide association studies have identified hundreds of genetic variants associated with blood 
pressure (BP), but sequence variation accounts for a small fraction of the phenotypic variance. 
Epigenetic changes may alter the expression of genes involved in BP regulation and explain part of the 
missing heritability. We therefore conducted a two-stage meta-analysis of the cross-sectional 
associations of systolic and diastolic BP with blood-derived genome-wide DNA methylation measured on 
the Infinium HumanMethylation450 BeadChip in 17,010 individuals of European, African American, and 
Hispanic ancestry. Thirteen of 31 discovery stage cytosine-phosphate-guanine (CpG) dinucleotides 
replicated after Bonferroni correction (discovery: N=9,828, p value<1.0 x 10-7; replication: N=7,182, p 
value<1.6 x 10-3). The replicated methylation sites are heritable (h2>30%) and independent of known BP 
genetic variants, explaining an additional 1.4% and 2.0% of the interindividual variation in systolic and 
diastolic BP, respectively. Bidirectional Mendelian randomization among up to 4,513 individuals of 
European ancestry from four cohorts suggested that methylation at cg08035323 (TAF1B-YWHAQ) 
influences BP, while BP influences methylation at cg00533891 (ZMIZ1), cg00574958 (CPT1A), and 
cg02711608 (SLC1A5). Gene expression analyses further identified six genes (TSPAN2, SLC7A11, 
UNC93B1, CPT1A, PTMS, and LPCAT3) with evidence of triangular associations between methylation, 
gene expression, and BP. Additional integrative Mendelian randomization analyses of gene expression 
and DNA methylation suggested the expression of TSPAN2 is a putative mediator of association between 
DNA methylation at cg23999170 and BP. These findings suggest that heritable DNA methylation plays a 
role in regulating BP independently of previously known genetic variants.  
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Introduction 
Elevated blood pressure (BP) confers a higher risk of heart disease, stroke, diabetes, dementia, renal 
failure, and pregnancy-related complications and is a leading risk factor for death worldwide.1 BP is a 
highly heritable trait2 and recent genetic studies have revealed part of its complex genetic 
architecture,3–11 yet the genetic variants identified to date only account for a small fraction of its 
phenotypic variance.3,6,8,12 Complex phenotypes, such as BP, often result from the interplay between 
genetic and environmental influences. DNA methylation, the covalent binding of a methyl group to the 
5’ carbon of cytosine-phosphate-guanine (CpG) dinucleotide sequences in the genome, plays a critical 
role in the regulation of gene expression and may reflect a link between genes, environment, and 
complex phenotypes such as BP. Evidence is beginning to emerge that epigenetic modifications in genes 
relevant to BP may account for part of its regulation.13 Variation in DNA methylation may thus explain 
additional phenotypic variation in BP and provide new clues to the biological processes influencing its 
regulation. 
We conducted genome-wide DNA methylation meta-analyses for systolic and diastolic BP with a 
discovery phase and independent replication among 17,010 individuals of European (EA), African 
American (AA), and Hispanic ancestries in the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium. DNA methylation was measured in peripheral blood samples. We 
further sought to identify transcriptional changes for the replicated CpG sites and used Mendelian 
randomization techniques to explore the causal relationship between DNA methylation and BP. We 
report that the effect of DNA methylation on BP is likely independent of previously known genetic 
variants, representing new insights into the biological mechanisms underlying BP regulation.  
Material and Methods 
Study Populations 
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The discovery and replication studies were conducted in the framework of the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) consortium, which comprises multiple population-
based cohort studies.14 Cohorts participating at the discovery stage included 9,828 individuals of EA and 
AA ancestries in the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study 
(CHS), Framingham Heart Study (FHS), Genetic Epidemiology Network of Arteriopathy (GENOA) study, 
Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study, Lothian Birth Cohort 1936 
(LBC1936), Normative Aging Study (NAS), Rotterdam Study (RS), and TwinsUK registry. Cohorts 
participating at the replication stage consisted of 7,182 additional individuals of EA, AA, and Hispanic 
ancestries in the Amish Complex Disease Research Studies (Amish), ARIC, the Multi-Ethnic Study of 
Atherosclerosis (MESA), RS, adults in the Saguenay Youth Study (SYS), and the Women’s Health Initiative 
(WHI). Details for each cohort are provided in the supplementary material. All studies obtained written 
informed consent from participants and were approved by local institutional review boards and ethics 
committees. 
Blood Pressure Measurements 
Epigenome-wide association studies (EWAS) were conducted for systolic and diastolic BP, in mmHg. In 
each cohort BP was measured in a sitting position after a period of rest and an average of sequential 
readings was used as the phenotype for each analysis. For most cohorts BP was measured concurrently 
at the time of tissue collection for DNA methylation profiling, or in as close proximity as available for 
TwinsUK (0.8 years) and SYS adults (3.1 years). To adjust for the use of antihypertensive medication, we 
used the standard adjustment of adding 15 mmHg and 10 mmHg to measured systolic and diastolic BPs, 
respectively, when the use of any antihypertensive medications were self-reported. 
DNA Methylation Profiling 
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DNA methylation was measured on the Infinium HumanMethylation450 (450k) BeadChip (Illumina Inc, 
San Diego, CA) in all cohorts using whole blood samples, excepting that GOLDN measured DNA 
methylation in CD4+ T-cells. To correct the beta value distributions of the two types of probes on the 
450k array, each cohort normalized methylation beta values using BMIQ,15 DASEN,16 ComBat,17 SWAN,18 
or quantile normalization. LBC1936 did not normalize methylation beta values prior to analyses. 
Cohort-Level Association Analyses 
In each cohort, race-stratified linear mixed effect models were used to estimate associations adjusting 
for age, sex (in samples including men and women), blood cell counts, body mass index, smoking 
(current/former/never), and ancestry, as well as fixed and/or random effects for technical covariates to 
control for batch effects. Surrogate variables were calculated and adjusted in the modeling for ARIC AAs 
and FHS due to batch effects not controlled by other modeling techniques. The Amish, FHS, GOLDN, and 
TwinsUK accounted for sample relatedness in all analyses. Study-specific modeling details can be found 
in the Supplement. 
Epigenome-wide Meta-Analyses 
Effect estimates from all cohorts were combined using inverse variance fixed effects meta-analysis using 
GWAMA.19 We assessed heterogeneity of effect estimates between strata of races, sexes, and 
methylation tissue source among discovery cohorts using a 1 degree of freedom chi-square test for 
effect differences between strata; no heterogeneous effects were observed so all cohorts were included 
in a single meta-analysis. Meta-analyses were conducted separately for the discovery and replication 
cohorts to identify probes associated with BP. Statistical significance was Bonferroni-corrected for the 
epigenome-wide discovery meta-analysis (p value<1.0 x 10-7) and the number of discovery CpG sites 
sought for replication in the second meta-analysis. An overall meta-analysis was additionally performed 
to combine effect estimates across all cohorts. Significant CpG sites were annotated using information 
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provided by Illumina, including chromosome, position (GRCh37/hg19), UCSC gene names, relationship to 
CpG islands, location in gene enhancer regions, and DNase I hypersensitivity sites (DHS). To assess the 
impact of antihypertensive medication use on our top findings, we additionally performed an overall 
meta-analysis among all individuals reporting no use of antihypertensive medications. For the top 
findings in the discovery meta-analysis, we compared effect and standard error estimates to those 
estimated in the non-medicated meta-analysis.  
Percent Variance Explained 
Percent variance explained was calculated in the ARIC AA and EA samples included in discovery and 
replication meta-analyses, as well as validated in a sample from the FHS Third Generation not included 
in the meta-analysis (N=1,516). Methylation profile scores for BP were calculated as the weighted sum 
of CpG sites significant for either BP trait in the replication and overall meta-analyses, with weights 
coming from the magnitude and direction of effects in the overall meta-analysis. Selection of CpGs from 
meta-analyses including the prediction samples could overestimate percent variance explained, so 
additional meta-analyses were conducted excluding the ARIC samples to identify CpGs for their 
respective methylation profile scores. The probe sets based on exclusion of the ARIC samples and the 
probes identified in the primary replication and overall meta-analyses were used to generate 
methylation profile scores in the FHS sample. Race- and cohort-stratified linear regression models were 
used to estimate the percent of age-, sex-, and BMI-adjusted systolic and diastolic BP variances 
explained by each methylation profile score; ARIC models were additionally adjusted for visit and study 
site, and ARIC AA and FHS models included surrogate variables. Percent variance explained by the 
methylation profile scores is reported as the adjusted R2 from each model and compared to models 
without methylation profile scores (covariate-only models). We additionally assessed genetic risk scores 
derived using effect estimates from the UK Biobank for 146 previously reported independent variants 
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(r2<0.2) and 115 validated novel variants11 among the FHS Third Generation sample with available 
genetic data (N=1,421). 
Heritability 
The narrow-sense heritability estimate of a DNA methylation trait (β score) (denoted as ℎ𝐶𝑝𝐺_𝑚𝑒𝑡ℎ𝑦
2 ) was 
the proportion of the additive polygenic genetic variance of the total phenotypic variance of a DNA 
methylation trait: ℎ𝐶𝑝𝐺_𝑚𝑒𝑡ℎ𝑦
2 = σA
2 /σ𝐶𝑝𝐺_𝑚𝑒𝑡ℎ𝑦
2 , where σA
2  denotes the additive polygenic genetic 
variance and σ𝐶𝑝𝐺_𝑚𝑒𝑡ℎ𝑦
2  denotes the total phenotypic variance of a DNA methylation trait. Heritability 
estimation for all DNA methylation traits was performed using the FHS-Offspring participants (N=2,377). 
Functional Tissue and Gene Set Enrichment Analyses 
Functional DNA elements regulated by methylation may be tissue specific, so the set of replicated CpGs 
was used to identify tissue and cell type specific signals using experimentally-derived Functional element 
Overlap analysis of ReGions from EWAS (eFORGE).20 After pruning results for CpG sites within 1kb (2 
probes removed), we matched the top eleven EWAS signals for overlap with DNase I hypersensitive sites 
using data from ENCODE and Roadmap Epigenomics. One thousand matched sets were used with the 
450k array as the background set. FDR correction was applied to the results. 
Gene Set Enrichment Analysis (GSEA)21 was conducted on the results of the overall meta-analyses for 
systolic and diastolic BP. For each gene annotated to DNA methylation measured on the 450k array, a 
composite ranking for BP was generated based on the CpG site with the minimum p value for either 
trait. All gene ontology biological process categories (c5.bp.v5.1) were assessed for enrichment at FDR 
Q< 0.05. 
Methylation Quantitative Trait Loci 
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To determine methylation levels at CpG sites that may be influenced by nearby DNA sequence, 
methylation quantitative trait loci (meQTL) analyses were performed for the 13 replicated BP CpGs in EA 
individuals from ARIC (N=948), FHS (N=2,357), and RS (N=731) and AA individuals from ARIC (N=2,173) 
and GENOA (N=422). Residuals were obtained from regressing inverse-normal transformed methylation 
beta values on the first ten methylation principal components (PCs) and up to the first ten genetic PCs. 
The residuals were then regressed on 1000Genomes Phase I imputed SNPs within 50kb of the probe 
(CpG position ± 25kb, GRCh37/hg19). SNPs with low imputation quality (r2 < 0.3), low frequency variants 
(MAF < 0.05), and SNPs present in only one cohort were removed from analyses. Results for each probe 
were combined using race-stratified p-value-based meta-analysis weighted by sample size and direction 
of effects using METAL.22 Significant meQTLs were determined using a Bonferroni correction for all 
meQTLs tested in each race (EA: 0.05/1,447=3.5 x 10-5; AA: 0.05/1,952=2.6 x 10-5). To maximize 
statistical power for identifying meQTLs associated with BP, we then searched the largest genome-wide 
association studies (GWAS) for BP in each race for suggestive association of meQTL regions with BP. 
To assess the association of SNPs reported by Kato et al23 whose association may be mediated by DNA 
methylation we additionally performed meQTL analyses for 35 sentinel SNPs and additional GWAS loci 
in high linkage disequilibrium (LD) with these regions.3,4,23–31 We assessed the association of DNA 
methylation within 1Mb (CpG position +/-500kb) of GWAS SNPs among ARIC EAs (N=790) using the 
previously described methodology. SNPs associated with methylation after Bonferroni correction for the 
28 meQTLs reported by Kato et al (p value<0.0018) were then assessed for association with BP before 
and after adjustment for methylation at the CpG site. We additionally assessed the association of these 
CpG sites with BP in our overall meta-analysis. 
Bidirectional Mendelian Randomization 
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To assess the directional association of DNA methylation and BP, we conducted bidirectional Mendelian 
randomization (MR) using 1000Genomes imputed SNPs among EA individuals in ARIC, FHS, RS, and WHI-
EMPC (N=4,513). Forward MR was used to identify replicated CpG sites which may have an effect on BP. 
Instrumental variables (IVs) for DNA methylation were drawn from the meQTLs estimated among EAs 
and pruned for independence (r2<0.2). Forward MR was conducted for the six sentinel CpG sites with at 
least three independent meQTLs, which is the minimum number of IVs needed to perform multi-
instrument MR. Reverse MR was used to identify DNA methylation at the 11 sentinel CpG sites that may 
be caused by BP. The 29 independent loci reported as associated with BP by the International 
Consortium for Blood Pressure (ICBP) were selected as IVs. The SNP rs805303 was not imputed in 1000 
Genomes and rs805301 was used as a proxy when available (r2=1.0 in HapMap).  
Each cohort estimated the associations of IVs with systolic BP, diastolic BP, and DNA methylation at the 
respective CpG sites. Cohort-level effect estimates for each IV were combined using inverse variance-
weighted meta-analyses in METAL.22 For each CpG in forward and reverse MR, causation was formally 
tested based on the inverse variance-weighted effects across all IV-BP and IV-CpG estimates using the R 
package MendelianRandomization.32 Tests for causation with p value<0.05 were considered significant. 
To ensure the validity of the inverse-variance weighted approach, the IVs were assessed for pleiotropy 
using the MR-Egger test. Inverse-variance weighted MR is invalid in the presence of pleiotropic effects of 
IVs, so Egger regression estimates of causality were assessed only when pleiotropy was indicated at a 
particular CpG site.  
Associations of DNA Methylation and Gene Expression 
Association tests of BP-associated CpGs with transcripts that were located within +/- 1MB distance of 
the corresponding CpGs were performed in 2,216 FHS-Offspring samples and 730 RS samples whose 
DNA methylation and gene expression data were both available. In FHS, linear mixed effect regression 
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models were used with DNA methylation β scores as the dependent variable, gene expression as 
independent variables, age, sex, and technical covariates as fixed effects, and family structure as a 
random effect. In RS, we first created residuals for both DNA methylation and mRNA expression after 
regressing out age, sex, blood cell counts (fixed effect) and technical covariates (random effect). We 
then examined the association between the residuals of DNA methylation (independent variable) and 
mRNA expression (dependent variable) using a linear regression model.  Estimates of the gene 
expression-methylation associations in RS and FHS were combined using sample size weighted fixed 
effects meta-analysis based on P-values and direction of effects using GWAMA.19 
Associations of Gene Expression and BP  
Differential gene expression analysis of the transcripts assessed for association with DNA methylation 
were performed for systolic BP, diastolic BP, and hypertension in 3,679 FHS Offspring and 3rd-Gen 
participants who were not receiving anti-hypertensive treatments. Hypertension was defined as systolic 
BP ≥140 mmHg or diastolic BP ≥90 mmHg. See details in Huan et al.33  
Two-Step Mendelian Randomization for Relationship of DNA Methylation, Gene Expression, and BP 
To identify gene transcription that functionally mediates the relationship of DNA methylation and BP, 
we performed a two-step MR technique for genes with expression associated with both DNA 
methylation and BP (FDR Q value<0.05). The first step was to establish a directional relationship 
between DNA methylation and gene transcription. IVs for DNA methylation were drawn from estimated 
meQTLs pruned to be independent (r2<0.2). Using whole blood eQTLs estimated in the Genotype-Tissue 
Expression (GTEx) project, we verified the association of each IV with the implicated gene expression. In 
the second step, IVs for each implicated gene were selected from the GTEx whole blood dataset in order 
to establish a directional relationship between gene expression and BP. The top eQTL also present in the 
ICBP results was selected as the IV for each gene and assessed for association with systolic and diastolic 
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BP in ICBP published GWAS results. Genes with p value<0.05 at both steps were considered to mediate a 
directional relationship of the respective CpG and BP; correction for multiple testing is not used as 
strong associations of IVs with an outcome would violate the assumptions of Mendelian randomization. 
 
Results 
Cohort Characteristics 
Characteristics of the 14 studies participating in discovery and replication meta-analyses are presented 
in Table 1. Each cohort included middle-aged and older adults with a wide range of BP values. Mean 
systolic BP ranged from 116 mmHg in GOLDN to 152 mmHg among CHS AAs. Mean diastolic BP ranged 
from 68 mmHg in GOLDN to 89 mmHg in the RS replication sample. Prevalence of antihypertensive 
medication use varied with cohort age and health, with no use among the Amish to more than 62% 
among the CHS AA sample.  
Identification of Epigenome-wide CpG Sites Associated with Blood Pressure 
In the discovery stage, we conducted genome-wide associations of DNA methylation with systolic and 
diastolic BP in nine cohort studies (N=9,828). Multiethnic meta-analyses identified methylation at 31 
CpG sites associated with BP after Bonferroni correction for the number of DNA methylation CpG sites 
measured on the Illumina 450K array (p value<1.0 x 10-7; Table S1, Figures S1 and S2). Replication of the 
31 discovery CpG sites was sought in multiethnic meta-analyses of an additional six cohort studies 
(N=7,182). Methylation at 13 of the 31 discovery CpG sites was associated with BP at p value<0.0016 in 
the replication meta-analysis (0.05/31; Table 2). A schematic of the overall study design, including 
subsequent integrative analyses, is found in Figure S3. 
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The top two CpG sites for both systolic and diastolic BP were at the PHGDH locus, cg14476101 (systolic 
BP: coefficient=0.03% decrease in DNA methylation per 1 mmHg increase in BP, p value=2.7 x 10-34; 
diastolic BP: coefficient=0.04% decrease in DNA methylation per 1 mmHg increase in BP, p value=2.1 x 
10-21), and the SLC7A11 locus, cg06690548 (systolic BP: coefficient=0.02% decrease in DNA methylation 
per 1 mmHg increase in BP, p value=1.6 x 10-32; diastolic BP: coefficient=0.03% decrease in DNA 
methylation per 1 mmHg increase in BP, p value=7.9 x 10-26). cg14476101 is located on chromosome 
1p12 in the first intron of PHGDH, which encodes a phosphoglycerate dehydrogenase that catalyzes the 
rate-limiting step of serine biosynthesis. Located on chromosome 4q28.3, cg06690548 is in the first 
intron of SLC7A11, which encodes a sodium-independent cysteine/glutamate antiporter. All replicated 
CpG sites demonstrated associations of decreased DNA methylation with increases in BP (Table S1 and 
Figure S4). None of the replicated CpG sites cross-hybridize with sequence variation on the sex 
chromosomes and one CpG, SLC1A5 cg02711608, is polymorphic.34 An additional CpG site in SLC1A5, 
cg22304262, was also associated with BP and not polymorphic, so we did not exclude cg02711608 from 
our results. Narrow-sense heritability estimates of the 13 replicated CpG sites are moderate to high 
(h2=30-100%) relative to all epigenome-wide probes (average h2=12%; Table 3). Four of the 13 replicated 
CpG sites are in DNase I hypersensitivity sites and enhancer regions (Table S2). In PHGDH and SLC1A5 we 
identified two nearby CpG sites in each gene associated with BP. We regard cg14476101 as the sentinel 
CpG site in PHGDH and cg02711608 as the sentinel CpG site in SLC1A5 due to the strength of association 
p value with BP. Methylation levels at the two CpG sites in PHGDH were strongly correlated (AA and EA 
ρ=0.85), whereas the two CpG sites in SLC1A5 were only modestly correlated (AA: ρ =0.24, EA: ρ=0.37; 
Figure S5). Heterogeneity (Cochran’s Q) that may be attributable to cell type or race was observed in the 
discovery panel for SLC7A11 cg06690548 (Table S3), however, estimates in the replication panel for this 
CpG site were homogeneous with the same direction of effect and similar magnitude of association p 
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value as in the discovery meta-analyses (Table 2). All other reported CpG sites showed homogeneous 
effects in discovery and replication meta-analyses.  
We additionally conducted an overall meta-analysis of the discovery and replication cohorts and 
identified 126 CpG sites associated with BP after Bonferroni correction (p value<1.0x10-7; Table S4). To 
assess the effects of antihypertensive medication use, we performed epigenome-wide meta-analyses 
among the 9,894 individuals reporting no concurrent use of antihypertensive medications in the 
discovery and replication samples. This combined sample free from antihypertensive medication use is 
of comparable size to the discovery meta-analysis. We did not identify a large difference in effect 
estimates among the discovery CpG sites that met our strict replication standards (Figure S6). Many 
replicated CpGs were also epigenome-wide significant in the non-medicated analysis and three CpG sites 
on chromosome 10p15.1 were identified that were not significant in the discovery stage (Table S5). 
These CpG sites map to the first intron of PFKFB3, which encodes a glycolytic enzyme. 
Percent Variance Explained 
A methylation profile score based on the replicated CpG sites explained an additional 1.4% and 2.0% of 
the interindividual variation in systolic and diastolic BP, respectively, beyond the traditional BP 
covariates of age, sex, and BMI in an additional sample set from the FHS (N=1,516, Third Generation 
Cohort) not included in the discovery or replication meta-analyses (Figure 1). Expanding the DNA 
methylation risk score to include the 126 CpG sites that were significant in the overall meta-analysis did 
not explain additional phenotypic variance in samples of either ancestry. Up to 261 BP-associated 
genetic variants explained minimal variance in the FHS Third Generation sample set (N=1,421; 
PVE=0.003% - 0.1%). We elected to only report percent variances explained for methylation risk scores 
since our estimates are independent of the distally-located known genetic loci. 
Functional Tissue and Gene Set Enrichment Analyses 
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Tissues enriched for DNase I hypersensitive sites in regions of the replicated CpGs include blood cells, 
vascular tissues, brain tissues, and cardiac tissues (Figure S7). Gene set enrichment analysis (GSEA) was 
conducted for intragenic CpG sites identified in the overall meta-analyses for systolic and diastolic BP. 
DNA methylation associated with either BP trait mapped to genes involved in the transport of neutral 
amino acids (FDR Q=0.01; Figure S8). The transport of neutral amino acids was also identified as 
significantly enriched in the individual meta-analyses for systolic and diastolic BP (FDR Q<0.05). Forty-
three biological processes reached FDR Q<0.25 including brain development, hematopoietic or lymphoid 
organ development, and the transport of amino acids and amines.  
Methylation Quantitative Trait Loci 
We assessed genetic determinants of DNA methylation at the 13 replicated CpG sites in 4,036 EA 
individuals and 2,595 AA individuals in ARIC, FHS, GENOA, and RS. Nine of the 13 CpG sites 
demonstrated substantial evidence for methylation quantitative trait loci (meQTLs) in both ancestries 
(EA p value<3.5 x 10-5, AA p value<2.6 x 10-5), with evidence for weak meQTLs at one additional CpG site 
in each ancestry (Figure 2). We confirmed our estimated EA meQTLs in an independent EA dataset 
published by ARIES35 and found almost all estimated meQTLs were significant or in linkage 
disequilibrium (r2>0.2 or D’=1) with ARIES meQTLs. We assessed the association of EA meQTLs with BP in 
1000Genomes analysis by the International Consortium for Blood Pressure (ICBP)3 that is yet to be 
published. Seven of the ten CpGs demonstrated nominal association with systolic or diastolic BP (0.05>p 
value>1.0 x 10-3; Table S6). The strongest association with both systolic and diastolic BP was observed at 
rs561931 for PHGDH cg14476101 and cg16246545 (systolic p value=0.007; diastolic p value=0.01). 
Though association of exposure SNPs can serve as an indication of causality, we chose to formally test 
causality using multi-instrument Mendelian randomization, as follows, due to the complex genetic 
architecture of both DNA methylation and BP. 
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Bidirectional Mendelian Randomization 
DNA methylation can be the cause or consequence of complex phenotypes. To provide support for 
causal relationships between DNA methylation and BP, we conducted bidirectional Mendelian 
randomization among up to 4,513 EA individuals in ARIC, FHS, RS, and WHI-EMPC. We used inverse-
variance weighted tests to assess both forward causal roles of DNA methylation on BP and reverse 
causation where BP influences DNA methylation. For the six sentinel CpG sites with multiple genetic 
determinants, we were able to test forward causality using independent meQTLs as the instrumental 
variables. The mean causal effect estimated across its seven independent meQTLs suggests that 
methylation at cg08035323 (TAF1B-YWHAQ) influences BP (causal effect estimate = 20.9 (11.1) change 
in systolic BP, p value=0.009, and 15.1 (6.4) change in diastolic BP, p value=0.01, per one-percent change 
in DNA methylation; Table 4). There is also some evidence for reverse causation at cg08035323 (diastolic 
BP p value=0.02), however, the causal P-values for both BP traits are smaller for, and thus favor, forward 
causation. We performed an additional Mendelian randomization using BP effect estimates from ICBP 
and confirmed a causal relationship of methylation at cg08035323 with BP (systolic BP p value=0.007; 
Table S7).  
We assessed reverse causation for 11 sentinel CpG sites using 29 independent GWAS loci as 
instrumental variables to estimate the mean causal effect of BP on DNA methylation. In the absence of 
pleiotropic effects, inverse-variance weighted tests suggest that DNA methylation at cg00533891 
(systolic BP p value=0.04, diastolic BP p value=0.001) and SLC1A5 cg02711608 (systolic BP p value=0.02, 
diastolic BP p value=0.0495) is influenced by BP (Table 4). Reverse causation at both cg00533891 and 
SLC1A5 cg02711608 is also supported by the lower-powered Egger test for causality (Table S8). 
Additionally, tests for causality of the second CpG in SLC1A5, cg22304262 support reverse causality at 
this locus (diastolic BP p value=0.04; Table S8). The significant reverse causal effect estimates are 
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consistent in magnitude and direction with those estimated by our EWAS. We additionally identified 
significant pleiotropic effects of the instrumental variables with methylation at cg10601624 and diastolic 
BP (p value=0.02; Table S8). Pleiotropy overpowers the inverse-variance weighted test, and we did not 
identify a causal effect at cg10601624 using Egger regression (p value=0.9; Table S8). There was a 
significant test result for forward causation at cg00533891; however, there also was evidence of 
pleiotropic effects among the forward instrumental variables and both the inverse-variance weighted 
and Egger tests favored reverse causality (Table S8). We also identified an effect of diastolic BP on DNA 
methylation at cg00574958 using Egger regression (p value=0.04) in the presence of pleiotropic 
instrumental variables (Table S8). Using Mendelian randomization we demonstrate that complex 
phenotypes can have an effect on DNA methylation among top EWAS signals and that forward causality 
can be assessed when instrumental variables are available.  
Gene Expression Associations with Replicated CpG Sites and Blood Pressure Traits  
In whole blood gene expression analyses, four of the 13 replicated CpG sites were found to have one or 
more cis-located genes (TSPAN2, SLC7A11, UNC93B1, CPT1A, PTMS, and LPCAT3) where transcription 
levels are associated with both CpG methylation (FHS and RS, N=2,946) and systolic BP, diastolic BP, or 
hypertension (FHS, N=3,679; Tables 5 and S9). The direction of effects for all six gene transcripts was 
consistent with the negative associations of BP with DNA methylation at each CpG (Tables 2 and 5). The 
mRNA expression of TSPAN2 showed the strongest associations with both CpG methylation and BP 
among all transcripts tested. Methylation at cg23999170, located in the first intron of TSPAN2, was 
strongly associated with decreased expression of TSPAN2 in blood (p value=8.6 x 10-14) and expression 
levels were associated with systolic BP (p value=5.0E-29), diastolic BP (p value=1.3 x 10-16), and 
hypertension (p value=2.4 x 10-10).  
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We identified nominal triangular associations of gene expression levels with methylation at 11 of the 
replicated CpG sites (p value<0.05) and at least one BP trait (p value<0.05) and present estimates of 
association and correlation in Table S10. These genes include YWHAQ (cg08035323 and diastolic BP), 
PPIF (cg00533891 and diastolic BP), and GRLF1 (cg02711608/cg22304262 and diastolic BP).  
Two-Step Mendelian Randomization for Genes Mediating the BP-DNA Methylation Association 
We used two-step Mendelian randomization to characterize causal mediation by gene transcripts 
significantly associated with methylation and BP. Using expression data available from the Genotype-
Tissue Expression (GTEx) project and BP GWAS from ICBP, we first sought to establish a directional 
relationship from DNA methylation to gene expression, then a directional relationship from gene 
expression to BP. We showed that independent SNPs associated with methylation at cg23999170 are 
associated with expression of TSPAN2 and an additional independent variant associated with TSPAN2 
expression in blood is associated with BP (Table 6). The instrumental variables used for the exposures in 
each step achieved the associations needed to establish causality without showing strong evidence of 
association with the outcome that would invalidate the causal test (generally, 0.05>p value>1 x 10-5). 
Using two-step Mendelian randomization, we demonstrated that TSPAN2 expression in whole blood is 
influenced by methylation at cg23999170 and that TSPAN2 expression affects diastolic BP (Figure 3). 
Taken together, the direction of causality and our epigenome-wide estimate of association suggest that 
diastolic BP may increase by 5 mmHg for every 0.1% decrease in DNA methylation at cg23999170. 
Discussion 
In a two stage design of discovery and replication meta-analyses comprising 17,010 individuals, we 
identified DNA methylation at 13 CpG sites located in eight intragenic regions and three intergenic 
regions significantly associated with systolic or diastolic BP. These CpGs are heritable, which suggests 
DNA methylation that is the cause or consequence of BP may have a transgenerational effect. We 
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identified substantial cis-located genetic variation associated with methylation at many of these sites in 
both EA and AA populations, and these regions have moderate genetic associations with BP but are 
independent of the top GWAS loci previously reported in either race. Through cis gene expression 
analyses, we identified four CpGs significantly associated with one or more genes that may functionally 
connect DNA methylation and BP. Mendelian randomization techniques characterized the direction of 
association for six CpG sites with BP, including the mediation of a causal relationship of cg23999170 with 
BP through expression of TSPAN2. Through the analysis of DNA methylation, we have identified genes 
that provide insight into the biological mechanisms underlying BP regulation and target genes possibly 
affected by BP-induced DNA methylation.  
We identified expression of TSPAN2 to influence BP via DNA methylation. TSPAN2 encodes the 
tetraspanin 2 protein that is involved in signal transduction. TSPAN2 is highly expressed in vascular 
tissues and implicated in the contractile ability and differentiation of vascular smooth muscle cells.36 
Sequence variation mapped to TSPAN2 has previously been associated with large artery atherosclerosis-
related stroke37 and migraine38,39 and TSPAN2 suppresses inflammation in the central nervous system40. 
We additionally identified DNA methylation at cg08035323 to affect BP and the transcription of YWHAQ 
has a suggestive triangular relationship. YWHAQ encodes a 14-3-3 theta protein involved in signal 
transduction by binding to phosphoserine-containing proteins. YWHAQ has been implicated in 
phenotypes related to vascular response through transcriptional and DNA methylation changes in 
human preeclamptic placental tissues,41 DNA sequence variation associated with exercise heart rate 
response42, and an effect on cardiomyocyte survival in animal models.43 
We identified an effect of BP on DNA methylation at four of the 13 replicated CpG sites: ZMIZ1 
cg00533891, CPT1A cg00574958, and SLC5A1 cg02711608/cg22304262. Previous epigenome-wide 
association studies have identified relationships of CPT1A cg00574958 and SLC5A1 
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cg02711608/cg22304262 with other metabolic phenotypes, particularly lipids and adiposity (Table S11). 
An effect of triglycerides on methylation at cg00574958 has previously been identified,44 which supports 
our hypothesis that an underlying cardiometabolic disease process related to BP and lipids alters DNA 
methylation within CPT1A. Transcriptional changes caused by DNA methylation at these four CpG sites 
could affect the risk of downstream phenotypes. 
A recent GWAS identified 28 of 35 sentinel SNPs to have methylation-mediated associations with BP 
using a Mendelian randomization technique.23 In our overall meta-analyses, we assessed the association 
of the 28 CpG sites reported by Kato et al, but were not able to confirm the direct association of any of 
these CpG sites with BP (p value>1.0 x 10-5; Table S12). We further could not confirm the association of 
the sentinel SNPs with the CpG sites reported to mediate the associations with BP. However, we 
identified an association of rs12567136 (CLCN6) with methylation at an upstream CpG, cg20946054 
(DRAXIN). This CpG site has a nominal association with BP (systolic BP p value=0.0318, diastolic BP p 
value=0.0015) and adjustment for methylation at this locus attenuated the association of rs12567136 
with systolic BP but not diastolic BP (Table S13). Diastolic BP was the primary phenotype identified by 
Kato et al. Differences between our findings and those reported by Kato et al. may be due to differing 
linkage disequilibrium structure in the populations examined in the two studies.   
The strength of this study is our use of multiple data sources and analytic techniques to characterize 
functional relationships of DNA methylation and BP. We used strict replication standards to identify 13 
CpG sites associated with BP and characterized gene transcriptional changes that could underlie these 
associations. However, these CpG sites were identified through cross-sectional analyses and we were 
only able to characterize the direction of association for six CpG sites. Mendelian randomization requires 
exposure-predictive SNPs to be selected as instrumental variables. For three CpG sites we estimated no 
significant cis-meQTLs (cg19693031, cg06690548, and cg00574958) and an additional two CpG sites had 
24 
 
insufficient independent meQTLs to assess forward causation using multiple instrumental variables 
(cg18120259 and cg10601624), so we lacked the ability to perform causal tests for select CpG sites. We 
additionally a priori chose to examine gene expression 1Mb up- and downstream of each CpG site in 
whole blood, so more distal regulatory effects, and effects in different tissues, could have been missed. 
However, we did identify at least one biologically plausible gene to have a nominal triangular association 
with both methylation and BP for eleven of the replicated CpG sites, so it may be that larger sample 
sizes will uncover the functional and causal relationships of DNA methylation and BP. Despite these 
limitations, we discovered heritable CpG sites associated with BP among 17,010 individuals and showed 
that these CpGs explain additional phenotypic variance in an independent sample in which up to 261 BP-
associated genetic variants explained minimal trait variance. We characterized the methylation-BP 
relationship using gene expression analyses and Mendelian randomization techniques to both 
understand which genes may regulate BP and how BP may affect gene transcription. 
In conclusion, our genome-wide analysis of DNA methylation has uncovered loci influencing BP variation 
independently of underlying genetic variation. We additionally characterized functional and causal 
relationships connecting methylation at these loci with BP. In particular, we have identified TSPAN2 as a 
candidate gene for BP that is regulated by heritable DNA methylation. TSPAN2 and other methylated 
regions point to vascular contractility and inflammatory processes that functionally and causally connect 
DNA methylation and BP, and, thus, may represent new targets for the treatment and prevention of 
hypertension. Additional studies are needed to provide further mechanistic insights into the 
environmental exposures and genetic variation that influence DNA methylation and lead to high blood 
pressure. Nonetheless, our findings suggest that information on DNA methylation is likely to yield 
additional insights into the pathobiology of complex traits. 
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Figure Titles and Legends 
Figure 1 Percent variance explained by traditional covariates and methylation profile scores for 
systolic and diastolic BP. The plot presents adjusted R2 values from covariate-adjusted models including 
a methylation profile risk score based on methylation CpG sites identified to be associated with BP in the 
overall and replication meta-analyses. The number of CpG sites included in the methylation profile 
scores is indicated as n. Percent variance explained for the CpG sites identified in the primary replication 
and overall meta-analyses was calculated among an independent sample from FHS. The two ARIC 
samples participating in the discovery and replication stages were excluded from meta-analyses used to 
identify CpGs for their respective methylation risk scores, which caused the sets of methylation sites to 
differ. 
Abbreviations: AA, African American; ARIC, Atherosclerosis Risk in Communities; BP, blood pressure; 
CpG, cytosine-phosphate-guanine; EA, European Ancestry; FHS, Framingham Heart Study. 
Figure 2 Distribution of unpruned 1000Genomes imputed SNPs assessed for association with 
methylation relative to the CpG location (+/- 25kb). SNP position relative to the replicated methylation 
CpG position (X=0) is plotted against –log10 of the p value for meQTL meta-analysis in each race. SNPs 
above the red line are significant after Bonferroni correction for multiple testing (p value<3.0 x 10-5). 
Abbreviations:  AA, African American; bp, base pair; CpG, cytosine-phosphate-guanine; EA, European 
Ancestry; meQTL, methylation quantitative trait locus; SNP, single nucleotide polymorphism. 
Figure 3 Illustration of the relationship of methylation at cg23999170 with diastolic BP, mediated by 
expression of TSPAN2. Methylation at cg23999170 was identified as associated with diastolic BP in 
discovery and replication meta-analyses of genome-wide DNA methylation (N=17,010). Expression of 
TSPAN2 was associated with methylation at cg23999170 in meta-analyses of FHS and RS and diastolic BP 
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in FHS. The direction of arrows in the diagram are inferred from significant two-step Mendelian 
randomization using data from the Genotype-Tissue Expression project and International Consortium for 
Blood Pressure, which suggests that methylation at cg23999170 influences BP through the expression of 
TSPAN2. The epigenome-wide association of DNA methylation and diastolic BP is interpreted given the 
evidence of causal direction and based on a 0.1% change in DNA methylation at cg23999170. 
Abbreviations: DBP, diastolic blood pressure.
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Table 1 Characteristics of the discovery and replication cohorts 
      Age, years SBP, mmHg DBP, mmHg HTN AHT 
Cohort Race N Cohort Type Tissue Normalization Mean  SD Mean  SD Mean  SD % % 
Discovery (n = 9,828)             
ARIC AA 2,743 Unrelated Blood BMIQ 56.6 5.9 135.0 23.4 80.2 12.4 65.5 48.9 
CHS AA 196 Unrelated Blood SWAN 73.0 5.4 151.5 23.9 83.2 12.5 78.6 62.2 
CHS EA 189 Unrelated Blood SWAN 76.0 5.1 142.8 23.9 76.7 10.9 65.6 49.2 
FHS EA 2,645 Family Blood DASEN 66.4 8.9 128.6 17.2 73.4 10.0 59.0 49.0 
GENOA AA 239 Unrelated Blood SWAN 60.1 8.4 146.1 25.6 82.5 12.4 72.0 58.2 
GOLDN EA 822 Family CD4+ T cells ComBat 48.8 15.9 115.7 16.3 68.4 9.4 25.7 21.0 
LBC1936 EA 903 Unrelated Blood - 69.5 0.8 149.4 19.0 81.3 10.1 40.7 43.0 
NAS EA 674 Unrelated Blood BMIQ 72.5 6.8 139.5 18.9 81.9 10.3 71.0 58.2 
RS-III EA 727 Unrelated Blood DASEN 59.7 8.2 138.9 22.0 85.8 12.5 53.2 30.1 
TwinsUK EA 690 Twins Blood BMIQ 58.4 9.3 126.0 16.6 77.2 9.8 25.7 21.5 
Replication (n = 7,182)             
Amish EA 192 Family Blood Quantile 46.3 13.6 117.8 12.7 72.4 8.1 2.0 0.0 
ARIC EA 1,058 Unrelated Blood BMIQ 59.8 5.4 121.2 20.5 70.1 11.1 29.7 17.6 
MESA AA 236 Unrelated Blood Quantile 60.6 9.2 127.5 19.6 73.3 9.5 55.2 48.0 
MESA EA 566 Unrelated Blood Quantile 60.8 9.6 121.0 18.5 70.1 9.6 36.8 31.7 
MESA HL 381 Unrelated Blood Quantile 59.0 9.5 122.6 18.4 72.0 9.3 37.8 31.3 
RS-III EA 711 Unrelated Blood DASEN 67.5 6.0 151.3 24.0 88.7 13.0 71.5 43.3 
SYS adults EA 111 Unrelated Blood SWAN 47.2 4.9 131.5 15.3 79.5 8.4 29.7 8.1 
WHI-BAA23 AA 666 Unrelated Blood ComBat 62.8 6.7 140.9 21.1 83.3 10.9 65.0 54.7 
WHI-BAA23 EA 965 Unrelated Blood ComBat 68.4 6.2 136.5 21.1 78.2 11.1 48.5 34.6 
WHI-BAA23 HL 333 Unrelated Blood ComBat 62.3 6.8 133.3 20.7 78.6 10.8 47.3 35.2 
WHI-EPMC AA 556 Unrelated Blood BMIQ 62.8 7.0 131.5 18.1 77.4 9.6 60.4 55.2 
WHI-EMPC EA 1,092 Unrelated Blood BMIQ 64.7 7.1 127.5 17.7 74.5 9.4 42.9 30.5 
WHI-EMPC HL 315 Unrelated Blood BMIQ 61.6 6.2 127.2 18.2 74.8 9.5 41.9 29.5 
Hypertension is defined as systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. Antihypertensive treatment is defined as 
the self-reported use of any antihypertensive medication. WHI-EMPC normalized DNA methylation data using BMIQ and 
plate-adjusted using ComBat. The discovery and replication samples from RS-III do not include overlapping or related 
individuals. 
Abbreviations: AA, African American; AHT, antihypertensive treatment; BMIQ, Beta Mixture Quantile dilation; ComBat, 
combatting batch effects when COMbining BATches of microarray data; DASEN, background-adjusted (D) between-array 
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(S) without dye bias correction (N); DBP, diastolic blood pressure; EA, European ancestry; HL, Hispanic/Latino; HTN, 
hypertension; SBP, systolic blood pressure; SD, standard deviation; SWAN, Subset-quantile Within Array Normalization.  
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Table 2 Results of discovery, replication, and overall meta-analyses for CpG sites replicated for association with BP  
    Systolic BP  Diastolic BP 
    Discovery Replication Overall  Discovery Replication Overall 
CpG site Chr Position UCSC Gene Coeff p value Coeff p value Coeff p value  Coeff p value Coeff p value Coeff p value 
cg23999170 1 115628111 TSPAN2 -0.0001 2.7 x 10-6 -0.0001 1.6 x 10-5 -0.0001 1.5 x 10-10  -0.0002 6.4 x 10-8 -0.0002 3.4 x 10-7 -0.0002 1.9 x 10-13 
cg16246545 1 120255941 PHGDH -0.0002 2.4 x 10-10 -0.0002 3.3 x 10-14 -0.0002 1.2 x 10-22  -0.0002 2.2 x 10-4 -0.0003 4.3 x 10-7 -0.0002 1.1 x 10-9 
cg14476101 1 120255992 PHGDH -0.0003 1.5 x 10-16 -0.0004 7.0 x 10-21 -0.0003 2.7 x 10-34  -0.0004 6.0 x 10-11 -0.0005 1.9 x 10-12 -0.0004 2.1 x 10-21 
cg19693031 1 145441552 TXNIP -0.0002 7.7 x 10-13 -0.0003 3.8 x 10-19 -0.0002 3.1 x 10-29  -0.0002 6.0 x 10-7 -0.0004 7.5 x 10-10 -0.0003 1.8 x 10-14 
cg08035323 2 9843525 
 
-0.0001 4.2 x 10-5 -0.0001 4.1 x 10-3 -0.0001 9.6 x 10-7  -0.0003 1.4 x 10-8 -0.0002 2.6 x 10-4 -0.0003 2.6 x 10-11 
cg06690548 4 139162808 SLC7A11 -0.0001 3.4 x 10-16 -0.0002 8.3 x 10-20 -0.0002 1.6 x 10-32  -0.0002 5.5 x 10-14 -0.0003 9.9 x 10-14 -0.0003 7.9 x 10-26 
cg18120259 6 43894639 LOC100132354 -0.0001 1.5 x 10-8 -0.0002 9.4 x 10-15 -0.0002 2.2 x 10-21  -0.0002 1.9 x 10-5 -0.0003 6.9 x 10-10 -0.0002 8.9 x 10-14 
cg00533891 10 80919242 ZMIZ1 -0.0001 2.4 x 10-7 -0.0001 3.7 x 10-3 -0.0001 5.5 x 10-9  -0.0003 4.4 x 10-9 -0.0002 8.9 x 10-4 -0.0002 2.0 x 10-11 
cg17061862 11 9590431 
 
-0.0001 6.9 x 10-5 -0.0002 6.6 x 10-9 -0.0001 9.4 x 10-12  -0.0003 5.1 x 10-8 -0.0003 1.2 x 10-6 -0.0003 4.3 x 10-13 
cg00574958 11 68607622 CPT1A -0.0001 1.9 x 10-8 -4.8 x 10-5 1.4 x 10-6 -0.0001 1.2 x 10-13  -0.0001 5.9 x 10-7 -0.0001 2.5 x 10-4 -0.0001 3.0 x 10-10 
cg10601624 12 6404377 
 
-0.0001 6.6 x 10-8 -0.0001 1.6 x 10-10 -0.0001 2.4 x 10-16  -0.0001 3.5 x 10-7 -0.0002 1.7 x 10-7 -0.0002 4.3 x 10-13 
cg22304262 19 47287778 SLC1A5 -0.0001 5.4 x 10-10 -0.0001 8.7 x 10-9 -0.0001 1.4 x 10-17  -0.0002 6.0 x 10-7 -0.0002 4.9 x 10-5 -0.0002 9.6 x 10-11 
cg02711608 19 47287964 SLC1A5 -0.0001 3.0 x 10-11 -0.0001 1.1 x 10-11 -0.0001 2.0 x 10-21  -0.0002 3.2 x 10-5 -0.0002 3.0 x 10-6 -0.0002 4.3 x 10-10 
Position is Hg19. Coefficients give the percent change in DNA methylation for every 1 mmHg change in blood pressure. 
Abbreviations: BP, blood pressure; Chr, chromosome; Coeff, coefficient; CpG, cytosine-phosphate-guanine; UCSC, University of California Santa Cruz. 
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Table 3 Narrow-sense heritability estimated in the FHS for CpG sites replicated for association with BP 
CpG site Chr Position Gene CpG h2 (95% CI) 
cg23999170 1 115628111 TSPAN2 0.45 (0.39, 0.50) 
cg16246545 1 120255941 PHGDH 0.47 (0.41, 0.55) 
cg14476101 1 120255992 PHGDH 0.53 (0.43, 0.63) 
cg19693031 1 145441552 TXNIP 0.55 (0.47, 0.63) 
cg08035323 2 9843525  0.65 (0.57, 0.73) 
cg06690548 4 139162808 SLC7A11 0.35 (0.27, 0.44) 
cg18120259 6 43894639 LOC100132354 0.32 (0.26, 0.38) 
cg00533891 10 80919242 ZMIZ1 0.54 (0.47, 0.63) 
cg17061862 11 9590431  0.54 (0.46, 0.62) 
cg00574958 11 68607622 CPT1A 1.00 (0.95, 1.05) 
cg10601624 12 6404377  0.30 (0.27, 0.34) 
cg22304262 19 47287778 SLC1A5 0.46 (0.39, 0.52) 
cg02711608 19 47287964 SLC1A5 0.31 (0.28, 0.35) 
Epigenome-wide average heritability is 0.12. Position is Hg19. 
Abbreviations: Chr, chromosome; CpG, cytosine-phosphate-guanine.  
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Table 4 Bidirectional Mendelian randomization results showing the inverse-variance weighted effects of multiple SNPs used as instrumental 
variables in the association of DNA methylation and BP 
  
Forward Mendelian Randomization 
CpG  BP  
Reverse Mendelian Randomization  
BP  CpG 
CpG Trait 
IV SNPs, 
n 
Mean 
estimate (SE) p value  
IV SNPs, 
n 
Mean 
estimate (SE) p value 
cg00533891 SBP 6 -10.3 (13.5) -  29 -0.0008 (0.0004) 0.0388 
cg00533891 DBP 6 -14.9 (7.8) 0.0405  29 -0.0020 (0.0006) 0.0013 
cg00574958 SBP -     29 0.0001 (0.0001) 0.2301 
cg00574958 DBP -     29 0.0001 (0.0002) - 
cg02711608 SBP 3 -31.1 (30.2) 0.2953  29 -0.0006 (0.0002) 0.0204 
cg02711608 DBP 3 -30.2 (17.3) -  29 -0.0008 (0.0004) 0.0495 
cg06690548 SBP -     29 -0.0004 (0.0003) 0.2267 
cg06690548 DBP -     29 -0.0002 (0.0006) 0.7724 
cg08035323 SBP 7 20.9 (11.1) 0.0091  29 -0.0004 (0.0003) 0.2206 
cg08035323 DBP 7 15.1 (6.4) 0.0111  29 -0.0012 (0.0006) 0.0226 
cg10601624 SBP -     29 -0.0004 (0.0002) 0.1069 
cg10601624 DBP -     29 -0.0010 (0.0003) - 
cg14476101 SBP 7 -2.5 (14.3) 0.8669  29 -0.0001 (0.0005) 0.7977 
cg14476101 DBP 7 1 (5.6) 0.8623  29 -0.0002 (0.0008) 0.7757 
cg17061862 SBP 10 -8.6 (10.2) 0.4224  29 0.0002 (0.0004) 0.6574 
cg17061862 DBP 10 4.8 (5.1) 0.1112  29 0.0000 (0.0006) 0.9844 
cg18120259 SBP -     29 0.0001 (0.0003) 0.8084 
cg18120259 DBP -     29 -0.0002 (0.0005) 0.6968 
cg19693031 SBP -     29 0.0003 (0.0004) 0.3889 
cg19693031 DBP -     29 0.0006 (0.0006) 0.3509 
cg23999170 SBP 5 5.9 (18.4) 0.7547  29 0.0004 (0.0003) 0.1954 
cg23999170 DBP 5 -1.2 (10.6) 0.9151  29 0.0003 (0.0005) 0.6080 
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Causal mean effect and standard error estimates for the 11 sentinel CpGs are shown and causal p values have been omitted when IVs showed 
significant pleiotropic effects (p < 0.05). Mean forward causal estimates are in percent DNA methylation change per mmHg increase in BP; mean 
reverse causal estimates are mmHg change in BP per 0.01 percent change in DNA methylation. 
Abbreviations: BP, blood pressure; CpG, cytosine-phosphate-guanine; DBP, diastolic blood pressure; IV, instrumental variable; Pos, position; SBP, 
systolic blood pressure; SE, standard error; SNP, single nucleotide polymorphism.  
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Table 5 Genes in a cis-region (+/- 1Mb) of replicated CpG sites 1) associated with DNA methylation in meta-analyses of FHS and RS at FDR Q 
value <0.05, and 2) associated with BP traits with at least one FDR Q value <0.05 
   Gene Expression – DNA Methylation  Gene Expression – Blood Pressure Traits 
   FHS RS Meta-Analysis   
CpG site Chr Gene Coeff p value Coeff p value Z-score  FDR Q  Trait Coeff t-test FDR Q 
cg23999170 1 TSPAN2 -1.38 2.7 x 10-14 -1.92 0.0062 -7.32 2.8 x 10-12  SBP 0.0048 11.36 5.0 x 10-29 
          DBP 0.0054 8.43 1.3 x 10-16 
          HTN 0.1161 6.49 2.4 x 10-10 
   -1.38 2.7 x 10-14 -2.72 0.0005 -7.86 8.6 x 10-14  SBP 0.0048 11.36 5.0 x 10-29 
          DBP 0.0054 8.43 1.3 x 10-16 
          HTN 0.1161 6.49 2.4 x 10-10 
cg06690548 4 SLC7A11 -0.62 2.8 x 10-14 NA NA -7.61 2.2 x 10-13  SBP 0.0003 1.00 0.3173 
          DBP 0.0002 0.32 0.7471 
          HTN 0.0304 2.12 0.0338 
cg00574958 11 UNC93B1 0.46 0.1375 2.84 0.0130 2.81 0.0376  SBP -0.0006 -2.52 0.0472 
          DBP -0.0008 -2.06 0.0790 
          HTN -0.0184 -1.69 0.2399 
  CPT1A -2.95 1.4 x 10-13 -2.36 0.0003 -7.79 2.1 x 10-13  SBP 0.0007 2.03 0.0846 
          DBP 0.0014 2.65 0.0324 
          HTN 0.0225 1.56 0.2399 
cg10601624 12 PTMS -0.78 0.0002 -4.50 0.0020 -4.83 2.8 x 10-5  SBP 0.0009 2.40 0.0807 
          DBP 0.0015 2.67 0.0381 
          HTN 0.0170 1.10 0.8100 
  LPCAT3 0.58 0.0012 1.18 0.2404 3.13 0.0134  SBP -0.0010 -3.40 0.0069 
          DBP -0.0012 -2.73 0.0381 
          HTN -0.0302 -2.48 0.1321 
Abbreviations: Chr, chromosome; Coeff, coefficient; CpG, cytosine-phosphate-guanine; DBP diastolic blood pressure; FDR, false discovery rate; 
FHS, Framingham Heart Study; HTN, hypertension; RS, Rotterdam Study; SBP, systolic blood pressure.  
42 
 
Table 6 Two-step Mendelian randomization results for genes with transcription significantly associated with DNA methylation and BP 
  Step One: CpG  GE  Step Two: GE  BP 
  IV: meQTLs  GTEx eQTL   IV: eQTLs  ICBP SBP  ICBP DBP 
CpG site Gene SNP Pos p value  p value  SNP Pos p value  p value p value 
cg23999170 TSPAN2 rs4240539 
         
115,603,844  5.5 x 10-10 
 
0.0074 
 
rs12143357 
    
115,321,323  9.7 x 10-4 
 
0.0986 0.0003 
  rs72697925 
         
115,604,454  4.5 x 10-10 
 
0.0254 
 
   
 
  
  rs72697930 
         
115,613,073  2.2 x 10-20 
 
0.0512 
 
   
 
  
  rs1286366 
         
115,617,856  2.6 x 10-58 
 
0.3148 
 
   
 
  
  rs10858064 
         
115,625,696  8.2 x 10-12 
 
0.5198 
 
   
 
  
cg06690548 SLC7A11 NA  NA  NA 
 
NA 
 
rs17050398 
    
139,350,368  3.6 x 10-3 
 
0.0745 0.0852 
cg00574958 CPT1A NA  NA  NA 
 
NA 
 
rs546233 
      
69,311,449  1.7 x 10-3 
 
0.6250 0.8880 
 UNC93B1 NA  NA  NA 
 
NA 
 
rs1793252 
      
67,740,366  1.3 x 10-4 
 
0.2410 0.0747 
cg10601624 LPCAT3 rs984337 
              
6,383,525  8.8 x 10-6 
 
0.1149 
 
rs2110073 
        
7,075,882  8.2 x 10-4 
 
0.1920 0.2840 
  rs4764572 
              
6,417,998  3.1 x 10-5 
 
0.5567 
 
   
 
  
 PTMS rs984337 
              
6,383,525  8.8 x 10-6 
 
0.5104 
 
rs9668071 
        
7,123,076  1.9 x 10-3 
 
0.2590 0.6930 
  rs4764572 
              
6,417,998  3.1 x 10-5 
 
0.5109 
 
   
 
  
Position is Hg19. 
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Abbreviations: BP, blood pressure; CpG, cytosine-phosphate-guanine; DBP diastolic blood pressure; eQTL, expression quantitative trait locus; GE, 
gene expression; GTEx, Genotype-Tissue Expression project; ICBP, International Consortium for Blood Pressure Genome-Wide Association 
Studies; IV, instrumental variable; meQTL, methylation quantitative trait locus; Pos, position; SBP, systolic blood pressure; SNP, single nucleotide 
polymorphism. 
